Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia

Blood

Volumn 119, Issue 25, 2012, Pages 6155-6161

  Veys, Paul ^a   Wynn, Robert F ^b   Ahn, Kwang Woo ^c   Samarasinghe, Sujith ^a   He, Wensheng ^c   Bonney, Denise ^b   Craddock, John ^d   Cornish, Jacqueline ^e   Davies, Stella M ^f   Dvorak, Christopher C ^g   Duerst, Reggie E ^h   Gross, Thomas G ⁱ   Kapoor, Neena ^j   Kitko, Carrie ^k   Krance, Robert A ^l   Leung, Wing ^m   Lewis, Victor A ⁿ   Steward, Colin ^e   Wagner, John E ^o   Carpenter, Paul A ^p   Eapen, Mary ^c   more..

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j CHILDREN S HOSPITAL LOS ANGELES   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l TEXAS CHILDREN S HOSPITAL   (United States)

^m ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o UNIVERSITY OF MINNESOTA   (United States)

^p Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFANT; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; T CELL DEPLETION; WHOLE BODY RADIATION;

EID: 84862745582     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-405795     Document Type: Article

References (23)

1. Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Haematol. 2008;21(12):177-192. (Pubitemid 351712712)
2. Davies SM, Wang D, Wang T, et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(3):360-366.
3. Jacobsohn DA, Arora M, Klein JP, et al. Risk factors associated with nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011;118(16):4472-4479.
4. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
5. Socié G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylais with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-6382.
6. Soiffer RJ, Le Rademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963-6970.
7. Shaw BE, Apperley J, Russell NH, et al. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol. 2011;153(2):244-252.
8. Kennedy-Nasser AA, Bollard CM, Myers GD, et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008;14(11):1245-1252.
9. Przepiorka D, Weisdorf DJ, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
10. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13(5):1091-1112. (Pubitemid 29489294)
11. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data. 2nd Ed. New York, NY: Springer-Verlag; 2003.
12. Cox DR. Regression model and life tables. J R Stat Soc B. 1972;34(2):187-200.
13. Andersen PK, Klein JP, Zhang M-J. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489-1500. (Pubitemid 29296604)
14. Patel B, Kirkland KE, Szydlo R, et al. Favorable outcomes with alemtuzumab- conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica. 2009;94(10):1399-1406.
15. Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
16. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic stem cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108(8):2867-2873.
17. Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002;100(8):2697-2702.
18. Anasetti C, Logan BR, Lee SJ, et al. Increased incidence of chronic graft-versus-host disease and no survival advantage with filgrastim mobilized peripheral blood stem cells compared to bone marrow transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III prospective randomized trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1.
19. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22(24):4872-4880. (Pubitemid 46638610)
20. Shah AJ, Kapoor N, Crooks GM, et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant. 2007;13(5):584-593. (Pubitemid 46585929)
21. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either anti-thymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36(11):1001-1008. (Pubitemid 41741564)
22. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haplo-identical and matched unrelated donor stem cell transplantation. Blood. 2009;114(19):4283-4292.
23. Hanley PJ, Shatter DR, Cruz CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad anti-viral specificity after stem cell transplantation. Cytotherapy. 2011;13(8):976-986.